2016
DOI: 10.1590/0037-8682-0134-2016
|View full text |Cite
|
Sign up to set email alerts
|

Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
30
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
3

Relationship

3
6

Authors

Journals

citations
Cited by 27 publications
(31 citation statements)
references
References 40 publications
0
30
1
Order By: Relevance
“…Although CareStart™ G6PD rapid test has been demonstrated to have > 95% sensitivity in detecting G6PD deficient phenotypes [5][6][7][8] , there have been discrepant results. Particularly, low sensitivity among individuals with enzyme activity < 30% has been reported in Cambodia (68%) 9 and more recently in the Brazilian Amazon (61.5%) 10 .…”
Section: Dear Editormentioning
confidence: 99%
See 1 more Smart Citation
“…Although CareStart™ G6PD rapid test has been demonstrated to have > 95% sensitivity in detecting G6PD deficient phenotypes [5][6][7][8] , there have been discrepant results. Particularly, low sensitivity among individuals with enzyme activity < 30% has been reported in Cambodia (68%) 9 and more recently in the Brazilian Amazon (61.5%) 10 .…”
Section: Dear Editormentioning
confidence: 99%
“…However, no mention of a pale purple color background appeared in the first batches of CareStart TM G6PD manufacturer's instructions 11 . As a result, a pale purple background was classified as normal only by the Cambodian study, and later by the Brazilian study 9,10 . The most recent CareStart TM G6PD test instructions indicate that no color change or the appearance of a very faint purple color in the reading window within 10 min (borderline results) should be read as deficient 12 .…”
Section: Dear Editormentioning
confidence: 99%
“…The most widely used lateral flow assay is the CareStart G6PD RDT (Accessbio, USA) with operational characteristics suitable for application in the field [6]. The test has been evaluated thoroughly and in most cases found to perform comparably to the FST [3438]. It has a similar cut-off activity to the FST and hence it is not suitable for guiding treatment with TQ [6] however its superior operational characteristics and price [6, 37] make it a useful alternative to the FST prior to PQ treatment.…”
Section: Topic 2: Necessary Properties Of G6pd Test For Wide Scale Dementioning
confidence: 99%
“…Spectrophotometry is the gold standard test of G6PD activity, but requires specialised staff and laboratory facilities [48,49]. Until recently, the only point-of-care test for G6PD deficiency was the fluorescent spot test (FST).…”
Section: Screening For G6pd Deficiency and Future Options For Radicalmentioning
confidence: 99%